ANI Pharmaceuticals Proposes $560 Million Egetis Therapeutics Deal

By Grace Kim

ANI Pharmaceuticals has recommended a public offer to acquire Sweden-based Egetis Therapeutics for approximately $560 million. ANI values Egetis at SEK 5.6 billion, or SEK 11.25 per share, a 27% premium to its 60-day volume-weighted average share price.

ANI puts the implied enterprise value at approximately $434 million after adjusting for estimated net proceeds from Egetis’ planned sale of a Rare Pediatric Disease Priority Review Voucher. ANI said the offer includes Egetis’ outstanding convertible debt and warrants. ANI expects to finance the purchase with existing cash and new debt financing from JPMorgan Chase Bank.

What does EMCITATE add to ANI’s portfolio?

ANI described Egetis as a commercial-stage pharmaceutical company focused on treatments for rare diseases with significant unmet needs.

ANI said EMCITATE received European Commission approval on February 12, 2025, followed by U.S. Food and Drug Administration approval on September 28, 2026. It is the first and only approved treatment in the United States and Europe for peripheral thyrotoxicosis associated with monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome.

ANI describes MCT8 deficiency as an ultra-rare genetic disorder affecting approximately one in 70,000 males. The company says the condition can create severe lifelong health complications and significant challenges for patients, families and caregivers. EMCITATE treats adults and pediatric patients.

ANI argues EMCITATE’s commercial potential is supported by the limited treatment options for affected patients. ANI estimates EMCITATE could generate more than $300 million in peak annual sales within its approved indication.

ANI says regulatory exclusivity and intellectual property protections extend into 2045. They include New Chemical Entity exclusivity, orphan drug exclusivity in the United States and Europe, and an Orange Book-listed patent extending into mid-2045.

ANI Pharmaceuticals President and CEO Nikhil Lalwani said:

“This proposed acquisition further accelerates our transformation with a substantial majority of our revenues expected to be derived from higher margin rare disease products by decade’s end and supports our mission of serving vulnerable patient populations with unmet medical needs.”

“We have followed the Egetis team closely, and we have been deeply impressed by their commitment to patients with MCT8 deficiency and to the families who care for them.”

ANI would gain an approved product with more than $300 million in estimated peak annual sales and protection into 2045.

How will ANI commercialize EMCITATE and extend the franchise?

ANI plans to use its existing rare-disease infrastructure to support EMCITATE’s commercialization and broaden access. The company intends to build on Egetis’ U.S. launch preparations through ANI’s medical-affairs capabilities, patient-access programs, reimbursement expertise and commercial resources.

Egetis also brings a research and development team running a clinical program for tiratricol in resistance to thyroid hormone beta, another thyroid-hormone signaling disorder. ANI views the program as a development opportunity beyond EMCITATE’s approved indication.

ANI’s existing rare-disease business includes products serving patients across ophthalmology, rheumatology, nephrology, neurology and pulmonology. ANI says Egetis would broaden that portfolio and support sustainable growth from differentiated specialty therapies. In practical terms, ANI would add a follow-on clinical program to an approved commercial product.

What must happen before the deal closes?

Egetis Therapeutics’ board unanimously recommended that shareholders and holders of the relevant securities accept the offer. Egetis said shareholders representing approximately 42% of its outstanding shares have agreed, subject to specified conditions.

Completion requires acceptance by holders of at least 90% of outstanding shares, along with necessary regulatory approvals and other customary conditions. Egetis expects the acceptance period to begin around November 20, 2026, and conclude around December 18, 2026.

Separately, Egetis announced on November 4 that it had entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $190 million. ANI said the planned sale is reflected in the acquisition’s implied enterprise valuation, while certain proceeds also carry earn-out arrangements involving former owners of Rare Thyroid Therapeutics International.

ANI named Jefferies as sole financial advisor and Ropes & Gray and Mannheimer Swartling as legal counsel. Egetis named Centerview Partners sole financial advisor and Vinge legal counsel. The 42% backing provides a base, but the 90% threshold and regulatory approvals still need to be secured.

How does the deal change ANI’s revenue mix?

ANI expects higher-margin rare-disease products to account for a substantial majority of revenue by the end of the decade. ANI said the transaction would combine EMCITATE and Egetis’ development expertise with ANI’s commercial infrastructure, with the stated aims of expanding patient access, strengthening the portfolio and creating additional long-term revenue opportunities.

Lalwani said:

“The proposed transaction reflects the disciplined execution of the strategy we have consistently outlined: adding differentiated, durable commercial Rare Disease assets that leverage our existing expertise and infrastructure.”

“The acquisition of Egetis would strengthen our Rare Disease portfolio and development capabilities.”

“By leveraging our resources and the groundwork laid by Egetis, we estimate peak sales potential for EMCITATE of over $300 million in its approved indication coupled with durable protection into 2045, bolstering our long-term growth and profitability profile.”

“We believe that ANI is well-positioned to successfully bring EMCITATE to patients and caregivers.”

The next test is whether EMCITATE can deliver the more than $300 million in peak annual sales ANI estimates while higher-margin rare-disease products rise to a substantial majority of revenue by decade’s end.